Patients, disease, and transplant-related characteristics
| Variable . | Donor . | |||
|---|---|---|---|---|
| Sibling . | Parent . | |||
| NIMA mismatched . | NIPA mismatched . | Mother . | Father . | |
| N | 63 | 69 | 79 | 58 |
| Age (y), median (range) | 17 (2-50) | 20 (2-62) | 15 (1-40) | 17 (1-43) |
| Male sex (%) | 42 (67) | 39 (56) | 48 (61) | 33 (57) |
| Pretransplantation Karnofsky performance score less than 90% | 14 (24%) | 17 (27%) | 17 (24%) | 33 (65%) |
| Disease type | ||||
| AML (%) | 26 (41) | 14 (20) | 27 (34) | 20 (34) |
| ALL (%) | 23 (37) | 30 (44) | 36 (46) | 19 (33) |
| CML (%) | 14 (22) | 25 (36) | 16 (20) | 19 (33) |
| Disease stage at transplantation* | ||||
| Early (%) | 22 (35) | 23 (34) | 22 (28) | 14 (25) |
| Intermediate (%) | 21 (34) | 23 (34) | 26 (33) | 24 (44) |
| Advanced (%) | 19 (31) | 21 (32) | 30 (39) | 17 (31) |
| Disease duration longer than 12 mo (%) | 38 (60) | 29 (42) | 45 (57) | 33 (57) |
| Donor-recipient sex-match | ||||
| M-M (%) | 20 (32) | 19 (28) | — | 33 (57) |
| F-M (%) | 22 (35) | 20 (29) | 48 (60) | — |
| M-F (%) | 13 (20) | 16 (23) | — | 25 (43) |
| F-F (%) | 8 (13) | 14 (20) | 31 (40) | — |
| HLA-antigen class mismatched | ||||
| Class 1 (%) | 46 (73) | 43 (62) | 46 (58) | 35 (61) |
| Class 2 (%) | 13 (21) | 19 (28) | 17 (22) | 13 (22) |
| Classes 1 and 2 (%) | 4 (6) | 7 (10) | 16 (20) | 10 (17) |
| Number of HLA-antigen mismatched | ||||
| 1 Ag mismatch (%) | 59 (94) | 60 (87) | 26 (33) | 23 (40) |
| 2 Ag mismatch (%) | 4 (6) | 9 (13) | 53 (67) | 35 (60) |
| Conditioning regimen | ||||
| TBI and Cy with or without other (%) | 32 (51) | 35 (51) | 42 (53) | 31 (53) |
| TBI and other (%) | 5 (8) | 10 (14) | 8 (10) | 7 (12) |
| BuCy with or without other (%) | 22 (35) | 19 (28) | 19 (24) | 11 (19) |
| Other (%) | 4 (6) | 5 (7) | 10 (13) | 9 (16) |
| GVHD prophylaxis | ||||
| CsA with or without other (%) | 14 (22) | 17 (25) | 18 (23) | 10 (17) |
| MTX with or without other (%) | 6 (10) | 3 (4) | 5 (6) | 6 (10) |
| CsA and MTX with or without other (%) | 43 (68) | 49 (71) | 56 (71) | 42 (73) |
| Year of transplantation | ||||
| 1985 to 1989 (%) | 22 (35) | 23 (33) | 30 (38) | 20 (34) |
| 1990 to 1993 (%) | 22 (35) | 25 (36) | 24 (30) | 19 (33) |
| 1994 to 1997 (%) | 19 (30) | 21 (31) | 25 (32) | 19 (33) |
| Variable . | Donor . | |||
|---|---|---|---|---|
| Sibling . | Parent . | |||
| NIMA mismatched . | NIPA mismatched . | Mother . | Father . | |
| N | 63 | 69 | 79 | 58 |
| Age (y), median (range) | 17 (2-50) | 20 (2-62) | 15 (1-40) | 17 (1-43) |
| Male sex (%) | 42 (67) | 39 (56) | 48 (61) | 33 (57) |
| Pretransplantation Karnofsky performance score less than 90% | 14 (24%) | 17 (27%) | 17 (24%) | 33 (65%) |
| Disease type | ||||
| AML (%) | 26 (41) | 14 (20) | 27 (34) | 20 (34) |
| ALL (%) | 23 (37) | 30 (44) | 36 (46) | 19 (33) |
| CML (%) | 14 (22) | 25 (36) | 16 (20) | 19 (33) |
| Disease stage at transplantation* | ||||
| Early (%) | 22 (35) | 23 (34) | 22 (28) | 14 (25) |
| Intermediate (%) | 21 (34) | 23 (34) | 26 (33) | 24 (44) |
| Advanced (%) | 19 (31) | 21 (32) | 30 (39) | 17 (31) |
| Disease duration longer than 12 mo (%) | 38 (60) | 29 (42) | 45 (57) | 33 (57) |
| Donor-recipient sex-match | ||||
| M-M (%) | 20 (32) | 19 (28) | — | 33 (57) |
| F-M (%) | 22 (35) | 20 (29) | 48 (60) | — |
| M-F (%) | 13 (20) | 16 (23) | — | 25 (43) |
| F-F (%) | 8 (13) | 14 (20) | 31 (40) | — |
| HLA-antigen class mismatched | ||||
| Class 1 (%) | 46 (73) | 43 (62) | 46 (58) | 35 (61) |
| Class 2 (%) | 13 (21) | 19 (28) | 17 (22) | 13 (22) |
| Classes 1 and 2 (%) | 4 (6) | 7 (10) | 16 (20) | 10 (17) |
| Number of HLA-antigen mismatched | ||||
| 1 Ag mismatch (%) | 59 (94) | 60 (87) | 26 (33) | 23 (40) |
| 2 Ag mismatch (%) | 4 (6) | 9 (13) | 53 (67) | 35 (60) |
| Conditioning regimen | ||||
| TBI and Cy with or without other (%) | 32 (51) | 35 (51) | 42 (53) | 31 (53) |
| TBI and other (%) | 5 (8) | 10 (14) | 8 (10) | 7 (12) |
| BuCy with or without other (%) | 22 (35) | 19 (28) | 19 (24) | 11 (19) |
| Other (%) | 4 (6) | 5 (7) | 10 (13) | 9 (16) |
| GVHD prophylaxis | ||||
| CsA with or without other (%) | 14 (22) | 17 (25) | 18 (23) | 10 (17) |
| MTX with or without other (%) | 6 (10) | 3 (4) | 5 (6) | 6 (10) |
| CsA and MTX with or without other (%) | 43 (68) | 49 (71) | 56 (71) | 42 (73) |
| Year of transplantation | ||||
| 1985 to 1989 (%) | 22 (35) | 23 (33) | 30 (38) | 20 (34) |
| 1990 to 1993 (%) | 22 (35) | 25 (36) | 24 (30) | 19 (33) |
| 1994 to 1997 (%) | 19 (30) | 21 (31) | 25 (32) | 19 (33) |
Data are for patients after acute or chronic leukemia who received 1 or 2 antigen-mismatched sibling or parental transplants from 1985 to 1997, as reported to the IBMTR. TBI indicates total body irradiation; Cy, cyclophosphamide; Bu, busulfan; CsA, cyclosporine; MTX, methotrexate.
Early leukemia, first complete remission or first chronic phase; intermediate leukemia, greater than or equal to second complete remission; greater than or equal to second chronic phase or accelerated phase; advanced leukemia, patients never in remission, in any relapse or blast phase.